Oct 12, 2023 9:20am EDT MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
Oct 10, 2023 11:15am EDT MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients
Oct 03, 2023 8:01am EDT MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
Aug 08, 2023 8:00am EDT MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
Jul 11, 2023 8:00am EDT MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
Jul 10, 2023 8:00am EDT MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
Jun 20, 2023 8:00am EDT MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients
Jun 07, 2023 8:00am EDT MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program
